Azacitidine in Combination With Low Dose Intensity Venetoclax in Patients With AML Incl. Explorative AML Profiling

Clinical trial NCT05431257 · RECRUITING

Trial details

NCT number: NCT05431257
Sponsor: Rigshospitalet, Denmark
Status: RECRUITING
Phase: Phase 2
Study type: INTERVENTIONAL

Acute Myeloid Leukemia

Start date: 2022-05-24
Primary completion: 2031-09-01
Enrollment: 117

View on ClinicalTrials.gov

Track trials programmatically

Sponsors, conditions and status changes through the Atlas API.